Quintiles

Stories /
Healthcare /
Quintiles /

75% growth in employee numbers

Transformational growth to become the world’s largest provider of life sciences product development and integrated healthcare services

Investment date

2008 - 2016

Good to great

250%

EBITDA increased from $370m to $830m

Near doubling of revenue from $2.8bn to $4.5bn; EBITDA grew over 250%

75%

growth in employee numbers

Expanded the global employee base from c.20,000 to c.35,000 employees

9

acquisitions during ownership

Operates in over 100 countries

Listed on the NYSE in May 2013, becoming a member of the FORTUNE 500, and named in FORTUNE’s list of the “World’s Most Admired Companies”

Key events under our ownership

Completed nine acquisitions, expanded commercial services into the Middle East, North Africa and East Africa, and developed numerous clinical development and joint venture partnerships

Expanded Real-World & Late Phase offering through acquisition (Outcome Sciences) and strategic partnerships

Created end-to-end product development solution through the Q2 Solutions joint-venture with Quest Diagnostics

Helped develop or commercialise most of the top biopharmaceutical and biologic products on the market today